U.S. RESEARCH ROUNDUP-Okta, Salesforce, Sarepta Therapeutics

Reuters02-29

Feb 29 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Okta, Salesforce and Sarepta Therapeutics, on Thursday.

HIGHLIGHTS

* Clearwater Analytics Holdings Inc : JP Morgan cuts to neutral from

overweight

* Okta Inc : Piper Sandler raises target price to $110 from $85

* Salesforce Inc : Barclays raises target price to $355 from $325

* Sarepta Therapeutics Inc : Leerink Partners raises target price to $165

from $145

* Universal Health Services Inc : Leerink Partners raises target to $192 from

$174

Following is a summary of research actions on U.S. companies reported by Reuters on Thursday. Stock entries are in alphabetical order.

* Acadia Healthcare Company Inc : Leerink Partners raises target to $100 from $95

* Advance Auto Parts Inc : JP Morgan raises target price to $68 from $55

* Alkami Technology Inc : JP Morgan raises target price to $31 from $27

* Array Technologies Inc : Scotiabank cuts target price to $25 from $33

* Atea Pharmaceuticals Inc : Leerink Partners raises target price to $5 from $4

* Avidxchange Holdings Inc : Piper Sandler raises target price to $14 from $13

* Avidxchange Holdings Inc : Susquehanna raises target price to $16 from $15

* Clearwater Analytics Holdings Inc : JP Morgan cuts target price to $22 from $24

* Clearwater Analytics Holdings Inc : JP Morgan cuts to neutral from overweight

* Crowdstrike Holdings Inc : JP Morgan raises target price to $350 from $300

* Dine Brands Global Inc : Wedbush raises target price to $48 from $46

* Editas Medicine Inc : Leerink Partners raises target price to $10 from $9

* Gulfport Energy Corp : Truist Securities raises target price to $184 from $170

* Inari Medical Inc : BTIG cuts target price to $86 from $93

* Inari Medical Inc : Truist Securities cuts target price to $61 from $63

* Marvell Technology Inc : Oppenheimer raises target price to $80 from $70

* Mersana Therapeutics Inc : Truist Securities raises to buy from hold

* Monster Beverage Corp : Jefferies raises target price to $69 from $66

* Nutanix Inc : JP Morgan raises target price to $70 from $65

* Nutanix Inc : Piper Sandler raises target price to $76 from $67

* Okta Inc : BTIG raises target price to $124 from $100

* Okta Inc : Piper Sandler raises target price to $110 from $85

* Permian Resources Corp : Susquehanna raises target price to $16 from $15

* Revance Therapeutics Inc : Piper Sandler cuts target price to $20 from $42

* Rxsight Inc : JP Morgan raises target price to $62 from $40

* Salesforce Inc : Barclays raises target price to $355 from $325

* Salesforce Inc : Raymond James raises target price to $380 from $300

* Sarepta Therapeutics Inc : Leerink Partners raises target price to $165 from $145

* Schrodinger Inc : Piper Sandler cuts target price to $50 from $60

* Shoals Technologies Group Inc : Piper Sandler cuts target price to $16 from $20

* Silk Road Medical Inc : JP Morgan raises target price to $19 from $10

* Slr Investment Corp : JP Morgan cuts target price to $15 from $15.5

* Snowflake Inc. : D.A. Davidson cuts target price to $230 from $260

* Snowflake Inc. : Melius Research cuts target price to $185 from $202

* Snowflake Inc. : Scotiabank cuts target price to $207 from $226

* Steven Madden Ltd : Wedbush raises target price to $41 from $38

* United Parks & Resorts Inc : JP Morgan raises target price to $61 from $57

* Universal Health Services Inc : Leerink Partners raises target to $192 from $174

* Vacasa Inc : JP Morgan raises target price to $10 from $8

(Compiled by Bengaluru Newsroom)

((Diaries@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment